Use of CA125 and Complementary Biomarkers for the Early Detection of Ovarian Cancer in Low Risk Women
NCT00539162
This study is recruiting at 10 US sites in 8 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this clinical research study is to find out if combining a standard blood test (CA-125) that checks for ovarian cancer with other blood tests that check for related tumor markers may be helpful in the early detection of ovarian cancer in women who are at low risk. Tumor markers are substances in the blood that may be related to ovarian cancer.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Ovarian Cancer
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Not applicable
- Ages
- 50 to 74 years
- Sex
- Female
- Healthy volunteers
- Accepted
- Sponsor
- M.D. Anderson Cancer Center
- Last updated on ClinicalTrials.gov
- October 9, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Florida · 1
- Sylvester Comprehensive Cancer Center, Univ of Miami Miller School of Medicine · Miami, FL
Iowa · 1
- John Stoddard Cancer Center · Des Moines, IA
Minnesota · 1
- University of Minnesota · Minneapolis, MN
New Jersey · 1
- Carol G. Simon Cancer Center / Atlantic Health · Morristown, NJ
New York · 1
- University of Rochester Medical Center · Rochester, NY
Oklahoma · 1
- University of Oklahoma Health Sciences Center · Oklahoma City, OK
Rhode Island · 1
- Women's and Infant's Hospital · Providence, RI
Texas · 3
- University of Texas MD Anderson Cancer Center · Houston, TX
- Women's Hospital of Texas, Obstetrics and Gynecology Associates (OGA) · Houston, TX
- UT Health Science Center San Antonio · San Antonio, TX
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.